---
title: "Arrowhead Pharma Soars 22% as Plozasiran Hits Phase 3 Endpoint"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293499184.md"
description: "Arrowhead Pharma (ARWR.US) jumps 22% after plozasiran meets Phase 3 primary endpoint, cutting triglycerides by up to 81%."
datetime: "2026-07-22T16:20:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293499184.md)
  - [en](https://longbridge.com/en/news/293499184.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293499184.md)
---

# Arrowhead Pharma Soars 22% as Plozasiran Hits Phase 3 Endpoint

箭头制药 (ARWR.US) 盘中涨近 22%，现报 90.91 美元。

plozasiran 在 III 期临床试验中达到主要终点，可将甘油三酯水平降低高达 81%。该积极数据点燃市场热情，推动股价大幅上涨。

### Related Stocks

- [ARWR.US](https://longbridge.com/en/quote/ARWR.US.md)

## Related News & Research

- [How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses](https://longbridge.com/en/news/295480333.md)
- [California State Teachers Retirement System Has $9.05 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR](https://longbridge.com/en/news/294785404.md)
- [Arrowhead Pharma acquires FDA rare pediatric disease priority review voucher](https://longbridge.com/en/news/294869347.md)
- [Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | ARWR Stock News](https://longbridge.com/en/news/294737263.md)
- [The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Plozasiran’s Phase 3 Success And Zodasiran Milestone](https://longbridge.com/en/news/294635779.md)